source
- J&J invests $785M in Sail Biomedicines, secures option to buy for $2.58BJohnson & Johnson has agreed to pay $785 million up front to Sail Biomedicines, including a $465 million equity infusion and up to $140 million in milestone payments. The agreement also gives J&J a…
- FDA advisory panel backs Replimune’s melanoma immunotherapy combined with OpdivoThe FDA’s Cellular, Tissue and Gene Therapies advisory committee voted 10-3 to recommend Replimune’s RP1 immunotherapy, used together with Bristol Myers Squibb’s Opdivo, for patients with advanced…